MUSHROOM DERIVED COMPOUNDS UNVEILED NARINGIN AS A POTENTIAL MULTI-TARGETED ANTI-BREAST CANCER COMPOUND - AN IN-SILICO APPROACH

Year 2025, Volume: 49 Issue: 1, 21 - 41, 20.01.2025

Ravichandran Veerasamy , Raghuraman Seenivasan , Harish Rajak , Parasuraman Pavadai , Prabha Thangavelu

https://doi.org/10.33483/jfpau.1512113

Abstract

Objective: The study aimed to evaluate the multiple target effect of phytochemicals of mushroom against breast cancer using molecular docking and dynamics approach.
Material and Method: In this study, the binding affinity of forty mushroom phytochemicals with various breast cancer proteins such as epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), topoisomerase IIα and topoisomerase IIβ were investigated by docking study using the PyRx tool. The selected receptors are highly cancer influencing and they were selected based on literature. Further molecular dynamics studies were also carried out to confirm the stability and conformation of the naringin-protein complex. In-silico ADMET studies were also carried out to confirm the pharmacokinetic properties and toxicity of the mushroom phytochemicals.
Result and Discussion: From the results obtained, colossolactone G, antcin-A, and formipinioside had higher affinity to EGFR than normal neratinib. Furthermore, fomitoside K, naringin and antcin-A were found to have higher binding affinity than neratinib with HER2. Besides, ergone, naringin, and ergosterol showed higher binding affinity than doxorubicin during interactions with topoisomerase IIα. On the other hand, antrocin, ergosterol peroxide and naringin demonstrated higher binding affinity against topoisomerase IIβ than doxorubicin. Further molecular dynamics studies were also carried out to confirm the stability and conformation of the naringin-protein complex which revealed the best binding score against all the four tested enzymes. Overall, this study suggests naringin as the best ligand and may have great potential in breast cancer protein inhibitors development. To demonstrate their therapeutic promise against breast cancer, more in vitro and in vivo research might be required.

Keywords

Breast cancer, molecular docking, molecular dynamics, mushroom, naringin

MANTAR TÜRETİLMİŞ BİLEŞİKLER, NARİNGİN'İN POTANSİYEL ÇOK HEDEFLİ MEME KANSERİ KARŞITI BİR BİLEŞİK OLDUĞUNU ORTAYA ÇIKARDI - BİR İN-SİLİCO YAKLAŞIMI

Abstract

Amaç: Çalışma, mantar fitokimyasallarının meme kanserine karşı çoklu hedef etkisini moleküler yerleştirme ve dinamik yaklaşımı kullanarak değerlendirmeyi amaçladı.
Gereç ve Yöntem: Bu çalışmada PyRx aracını kullanarak kırk mantar fitokimyasalının epidermal büyüme faktörü reseptörü (EGFR), insan epidermal büyüme faktörü reseptörü 2 (HER2), topoizomeraz IIα ve topoizomeraz IIβ gibi çeşitli meme kanseri proteinlerine bağlanma afinitesi docking çalışmasıyla araştırıldı. Seçilen reseptörler yüksek oranda kansere etki etmektedir ve literatüre dayanılarak seçilmiştir. Naringin-protein kompleksinin stabilitesini ve konformasyonunu doğrulamak için daha ileri moleküler dinamik çalışmalar da yapıldı. Mantar fitokimyasallarının farmakokinetik özelliklerini ve toksisitesini doğrulamak için in-silico ADMET çalışmaları da yapıldı.
Sonuç ve Tartışma: Elde edilen sonuçlara göre kolossolakton G, antcin-A ve formipiniosidin EGFR'ye afinitesi normal neratinib'e göre daha yüksekti. Ayrıca fomitosid K, naringin ve antcin-A'nın HER2 ile neratinibden daha yüksek bağlanma afinitesine sahip olduğu bulunmuştur. Ayrıca ergon, naringin ve ergosterol, topoizomeraz IIα ile etkileşimler sırasında doksorubisinden daha yüksek bağlanma afinitesi göstermiştir. Öte yandan antrosin, ergosterol peroksit ve naringin topoizomeraz IIβ'ya karşı doksorubisinden daha yüksek bağlanma afinitesi göstermiştir. Test edilen dört enzimin tümüne karşı en iyi bağlanma skorunu ortaya koyan naringin-protein kompleksinin stabilitesini ve konformasyonunu doğrulamak için daha ileri moleküler dinamik çalışmalar da yapıldı. Genel olarak bu çalışma, naringinin en iyi ligand olduğunu ve meme kanseri protein inhibitörlerinin geliştirilmesinde büyük potansiyele sahip olabileceğini öne sürüyor. Meme kanserine karşı tedavi vaatlerini göstermek için daha fazla in vitro ve in vivo araştırmaya ihtiyaç duyulabilir.

Keywords

Mantar, meme kanseri, moleküler dinamik, moleküler kenetlenme, naringin

References

• 1. Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Cinicians, 71(3), 209-249. [CrossRef]
• 2. Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., Cardoso, F. (2019). Breast cancer. Nature Reviews Disease Primers, 5(1), 66. [CrossRef]
• 3. Tomao, F., Papa, A., Zaccarelli, E., Rossi, L., Caruso, D., Minozzi, M., Vici, P., Frati, L., Tomao, S. (2015). Triple-negative breast cancer: new perspectives for targeted therapies. Onco Targets and Therapy, 177-193. [CrossRef]
• 4. Marusyk, A., Polyak, K. (2010). Tumor heterogeneity: Causes and consequences. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1805(1), 105-117. [CrossRef]
• 5. Wang, N., Wang, Z.Y., Mo, S.L., Loo, T.Y., Wang, D.M., Luo, H.B., Yang, D.P., Chen, Y.L., Shen, J.G., Chen, J.P. (2012). Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer. Breast Cancer Research and Treatment, 134, 943-955. [CrossRef]
• 6. Chen, S., Huang, L., Liu, Y., Chen, C.M., Wu, J., Shao, Z.M. (2013). The predictive and prognostic significance of pre-and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer. European Journal of Surgical Oncology, 39(6), 619-626. [CrossRef]
• 7. Koren, R., Rath-Wolfson, L., Ram, E., Itzhac, O.B., Schachter, B., Klein, B., Gal, R., Dreznik, Z. (2004). Prognostic value of topoisomerase II in female breast cancer. Oncology Reports. 12(4), 915-919. [CrossRef]
• 8. Jang, J.Y., Kim, D., Kim, N.D. (2023). Recent developments in combination chemotherapy for colorectal and breast cancers with topoisomerase inhibitors. International Journal of Molecular Sciences, 24(9), 8457. [CrossRef]
• 9. Vanderbeeken, M.C., Aftimos, P.G., Awada, A. (2013). Topoisomerase inhibitors in metastatic breast cancer: overview of current practice and future development. Current Breast Cancer Reports, 5(1), 31-41. [CrossRef]
• 10. Ekor, M. (2014). The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. Frontiers in Pharmacology, 4, 177. [CrossRef]
• 11. Debnath, S., Sen, D. (2022). Mushrooms are potential foods against cancer: Identified by molecular docking and molecular dynamics simulation. Natural Product Research, 36(10), 2604-2609. [CrossRef]
• 12. Speck-Planche, A., Cordeiro, M.N.D.S. (2017). Fragment-based in-silico modeling of multi-target inhibitors against breast cancer-related proteins. Molecular Diversity, 21, 511-523. [CrossRef]
• 13. Sert, Y., Albayati, M.R., Şen, F., Dege, N. (2024). The DFT and in-silico analysis of 2,2′-((1e,1′e)-((3,3′-dimethyl-[1,1′-biphenyl]-4,4′diyl)bis(azanylylidene))bis(methanylylidene))diphenol molecule. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 687, 133444. [CrossRef]
• 14. Mahmudov, I., Demir, Y., Sert, Y., Abdullayev, Y., Sujayev, A., Alwasel, S.H., Gulcin, I. (2022). Synthesis and inhibition profiles of N-benzyl-and N-allyl aniline derivatives against carbonic anhydrase and acetylcholinesterase-A molecular docking study. Arabian Journal of Chemistry, 15(3), 103645. [CrossRef]
• 15. Patel, S., Goyal, A. (2012). Recent developments in mushrooms as anti-cancer therapeutics: A review. 3 Biotech, 2, 1-5. [CrossRef]
• 16. Blagodatski, A., Yatsunskaya, M., Mikhailova, V., Tiasto, V., Kagansky, A., Katanaev, V.L. (2018). Medicinal mushrooms as an attractive new source of natural compounds for future cancer therapy. Oncotarget, 9(49), 29259. [CrossRef]
• 17. Ozturk, M., Tel-Çayan, G., Muhammad, A., Terzioğlu, P., Duru, M.E. (2015). Mushrooms: A Source Of Exciting Bioactive Compounds. In: Atta-ur-Rahman (eds). Studies in Natural Products Chemistry, (pp. 363-456). Amsterdam: Elsevier. [CrossRef]
• 18. Shin, A., Kim, J., Lim, S.Y., Kim, G., Sung, M.K., Lee, E.S., Ro, J. (2010). Dietary mushroom intake and the risk of breast cancer based on hormone receptor status. Nutrition and Cancer, 62(4), 476-483. [CrossRef]
• 19. Vamanu, E. (2018). Bioactive capacity of some Romanian wild edible mushrooms consumed mainly by local communities. Natural Product Research, 32(4), 440-443. [CrossRef]
• 20. Vascellari, S., Zucca, P., Perra, D., Serra, A., Piras, A., Rescigno, A. (2021). Antiproliferative and antiviral activity of methanolic extracts from Sardinian Maltese Mushroom (Cynomorium coccineum L.). Natural Product Research, 35(17), 2967-2971. [CrossRef]
• 21. Muszyńska, B., Kała, K., Sułkowska-Ziaja, K. (2017). Edible mushrooms and their in vitro culture as a source of anticancer compounds. In: S. Malik, (eds), Biotechnology and Production of Anti-Cancer Compounds, (pp. 231-251). Cham: Springer. [CrossRef]
• 22. Hao, Y.F., Jiang, J.G. (2015). Origin and evolution of China Pharmacopoeia and its implication for traditional medicines. Mini Reviews in Medicinal Chemistry, 15(7), 595-603. [CrossRef]
• 23. Veerasamy, R., Karunakaran, R. (2022). Molecular docking unveils the potential of andrographolide derivatives against COVID-19: An in-silico approach. Journal of Genetic Engineering and Biotechnology, 20(1), 1-6. [CrossRef]
• 24. Mun, C.S., Hui, L.Y., Sing, L.C., Karunakaran, R., Ravichandran, V. (2022). Multi-targeted molecular docking, pharmacokinetics, and drug-likeness evaluation of coumarin based compounds targeting proteins involved in development of COVID-19. Saudi Journal of Biological Sciences, 29(12), 103458. [CrossRef]
• 25. Hui, L.Y., Mun, C.S., Sing, L.C., Rajak, H., Karunakaran, R., Ravichandran, V. (2023). Multi-targeted molecular docking and drug-likeness evaluation of some nitrogen heterocyclic compounds targeting proteins involved in the development of COVID-19. Medicinal Chemistry, 19(3), 297-309. [CrossRef]
• 26. Kalimuthu, A.K., Panneerselvam, T., Pavadai, P., Pandian, S.R., Sundar, K., Murugesan, S., Ammunje, D.N., Kumar, S., Arunachalam, S., Kunjiappan, S. (2021). Pharmacoinformatics-based investigation of bioactive compounds of Rasam (South Indian recipe) against human cancer. Scientific Reports, 11(1), 21488. [CrossRef]
• 27. Tumskiy, R.S., Tumskaia, A.V. (2021). Multistep rational molecular design and combined docking for discovery of novel classes of inhibitors of SARS-CoV-2 main protease 3CLpro. Chemical Physics Letters, 780, 138894. [CrossRef]
• 28. Vishvakarma, V.K., Singh, M.B., Jain, P., Kumari, K., Singh, P. (2022). Hunting the main protease of SARS-CoV-2 by plitidepsin: Molecular docking and temperature-dependent molecular dynamics simulations. Amino Acids, 1-9. [CrossRef]
• 29. Schüttelkopf, A.W., Van Aalten, D.M. (2004). PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallographica Section D: Biological Crystallography, 60(8), 1355-63. [CrossRef]
• 30. Rangsinth, P., Sillapachaiyaporn, C., Nilkhet, S., Tencomnao, T., Ung, A.T., Chuchawankul, S. (2021). Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: An in-silico approach. Journal of Traditional and Complementary Medicine, 11(2), 158-172. [CrossRef]
• 31. Suwannarach, N., Kumla, J., Sujarit, K., Pattananandecha, T., Saenjum, C., Lumyong, S. (2020). Natural bioactive compounds from fungi as potential candidates for protease inhibitors and immunomodulators to apply for coronaviruses. Molecules, 25(8), 1800. [CrossRef]
• 32. Skok, Z., Zidar, N., Kikelj, D., Ilaš, J. (2019). Dual inhibitors of human DNA topoisomerase II and other cancer-related targets. Journal of Medicinal Chemistry, 63(3), 884-904. [CrossRef]
• 33. Feldinger, K., Kong, A. (2015). Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer: Targets and Therapy, 147-162. [CrossRef]
• 34. Arthur, D.E. (2019). Molecular docking studies of some topoisomerase II inhibitors: Implications in designing of novel anticancer drugs. Radiology of Infectious Diseases, 6(2), 68-79. [CrossRef]
• 35. Lindorff-Larsen, K., Piana, S., Palmo, K., Maragakis, P., Klepeis, J.L., Dror, R.O., Shaw, D.E. (2010). Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins: Structure, Function, and Bioinformatics, 78(8), 1950-1958. [CrossRef]
• 36. Shukla, R., Tripathi, T. (2020). Molecular Dynamics Simulation of Protein and Protein-Ligand Complexes. In: D.B. Singh, (eds), Computer-Aided Drug Design, (pp.133-161). Singapore: Springer.
• 37. Chen, Z., Yi, J., Zhao, H., Luan, H., Xu, M., Zhang, L., Feng, D. (2021). Strength development and deterioration mechanisms of foamed asphalt cold recycled mixture based on MD simulation. Construction and Building Materials, 269, 121324. [CrossRef]
• 38. Aier, I., Varadwaj, P.K., Raj, U. (2016). Structural insights into conformational stability of both wild-type and mutant EZH2 receptor. Scientific Reports, 6(1), 34984. [CrossRef]
• 39. Schreiner, W., Karch, R., Knapp, B., Ilieva, N. (2012). Relaxation estimation of RMSD in molecular dynamics immunosimulations. Computational and Mathematical Methods in Medicine, 2012, 173521. [CrossRef]
• 40. Sargsyan, K., Grauffel, C., Lim, C. (2017). How molecular size impacts RMSD applications in molecular dynamics simulations. Journal of Chemical Theory and Computation, 13(4), 1518-1524. [CrossRef]
• 41. Justino, G.C., Nascimento, C.P., Justino, M.C. (2021). Molecular dynamics simulations and analysis for bioinformatics undergraduate students. Biochemistry and Molecular Biology Education, 49(4), 570-582. [CrossRef]
• 42. Zhu, J., Lv, Y., Han, X., Xu, D., Han, W. (2017). Understanding the differences of the ligand binding/unbinding pathways between phosphorylated and non-phosphorylated ARH1 using molecular dynamics simulations. Scientific Reports, 7(1), 12439. [CrossRef]
• 43. Egan, W.J., Merz, K.M., Baldwin, J.J. (2000). Prediction of drug absorption using multivariate statistics. Journal of Medicinal Chemistry, 43(21), 3867-3877. [CrossRef]
• 44. Ghose, A.K., Viswanadhan, V.N., Wendoloski, J.J. (1999). A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. Journal of Combinatorial Chemistry, 1(1), 55-68. [CrossRef]
• 45. Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J. (2012). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 64, 4-17. [CrossRef]